Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cost of Revenue: 2023-2025

Historic Cost of Revenue for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $1.4 million.

  • Tonix Pharmaceuticals Holding's Cost of Revenue fell 12.09% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 24.40%. This contributed to the annual value of $7.8 million for FY2024, which is 63.78% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Cost of Revenue of $1.4 million as of Q3 2025, which was down 58.22% from $3.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Cost of Revenue's 5-year high stood at $3.4 million during Q2 2024, with a 5-year trough of $943,000 in Q1 2025.
  • Its 3-year average for Cost of Revenue is $2.0 million, with a median of $1.7 million in 2024.
  • Data for Tonix Pharmaceuticals Holding's Cost of Revenue shows a maximum YoY crashed of 50.02% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Cost of Revenue (Quarterly) stood at $2.4 million in 2023, then tumbled by 50.02% to $1.2 million in 2024, then decreased by 12.09% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $3.3 million for Q2 2025, and $943,000 during Q1 2025.